Sarepta Therapeutics, Inc. SRPT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $730.8M-1.9% | $442.93M— | $399.36M-14.5% | $611.09M+68.4% | $744.86M+80.2% | ||
| $29.4M-29.0% | —— | $14.9M-65.7% | $37M-26.7% | $41.4M+1.7% | ||
| $10.59M+6.2% | $5.25M-49.8% | $18.45M+88.2% | $10.84M+24.3% | $9.98M+14.1% | ||
| $330.96M+174% | -$282.85M-278% | -$179.95M-635% | —— | -$447.51M-1,339% | ||
| 45.3%+105pp | -63.9%— | -45.1%-52.3pp | —— | -60.1%-68.8pp | ||
| $29.4M-29.0% | —— | $14.9M-65.7% | $37M-26.7% | $41.4M+1.7% | ||
| $6.93M-4.8% | $7.25M-7.2% | $4.04M-45.7% | $6.93M-0.4% | $7.29M+15.0% | ||
| $1.73M+107% | $16.38M+49.3% | $1.16M-68.1% | $19.26M+172% | $835K-8.1% | ||
| -$3.42M-106% | $0-100% | -$131.56M-277% | -$132.08M-602% | $57.38M+367% | ||
| $69.76M-60.7% | $0-100% | $83.02M+17.7% | $59.19M-42.2% | $177.36M+193% | ||
| $14.55M-3.5% | —— | $62.81M+36.5% | $22.19M+348% | $15.07M+551% | ||
| $23.42M+226% | $951K+38.4% | $6.77M-5.8% | $0-100% | $7.19M0.0% | ||
| $241K-98.1% | -$39.21M-180% | -$117.79M-956% | -$23.82M-160% | $12.47M-43.7% | ||
| -$134.39M+53.8% | $96.21M-87.4% | —— | —— | -$291.18M-233% | ||
| -$202.68M+65.3% | —— | -$14.59M+79.4% | —— | -$583.44M-141% | ||
| $1.29M+176% | -$2.62M— | -$1.14M+62.8% | -$2.87M-129% | -$1.69M-34.3% | ||
| $170.2M+281% | —— | —— | —— | $44.66M-79.4% | ||
| $1M-55.3% | $138K— | $5.31M— | $188K— | $2.24M-77.6% | ||
| $2.08M-95.2% | $3.59M-90.6% | $22.93M-38.5% | $31.8M+9.0% | $43.65M+34.5% | ||
| $38.89M-4.6% | $99.94M-89.6% | $86.55M-70.9% | $68.63M-73.8% | $40.76M-91.5% | ||
| $29.4M-29.0% | $30.02M-39.6% | $14.93M-65.6% | $37.03M-26.7% | $41.43M+1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.